Silvercrest Asset Management’s Bicycle Therapeutics BCYC Stock Holding History

Silvercrest Asset Management’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-428,684	Closed	-$1.99M	–	852
2026 Q1	$1.99M	Sell	428,684 -48,292	-10%	-$276K	0.01%	530
2025 Q4	$3.38M	Hold	476,976	–	–	0.02%	477
2025 Q3	$3.69M	Buy	476,976 +211,283	+80%	+$1.59M	0.02%	465
2025 Q2	$1.85M	Hold	265,693	–	–	0.01%	564
2025 Q1	$2.26M	Buy	265,693 +127,953	+93%	+$1.51M	0.02%	526
2024 Q4	$1.93M	Sell	137,740 -1,353	-1%	-$29K	0.01%	535
2024 Q3	$3.15M	Buy	+139,093	New	+$3.21M	0.02%	436

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Silvercrest Asset Management's BCYC Position: Q2 2026 in Review

Silvercrest Asset Management sold out of Bicycle Therapeutics (BCYC) in Q2 2026, closing a stake of 428,684 shares — an estimated $1.99M sold.

Silvercrest Asset Management first reported a position in BCYC in Q3 2024 and held it in 7 quarters. The position peaked at $3.69M in Q3 2025. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Silvercrest Asset Management reported no remaining Bicycle Therapeutics position as of Q2 2026 after selling out during the quarter.
Silvercrest Asset Management sold 428,684 Bicycle Therapeutics shares in Q2 2026, an estimated $1.99M.
Silvercrest Asset Management first reported a position in Bicycle Therapeutics in Q3 2024 and held it in 7 quarters.
Silvercrest Asset Management's Bicycle Therapeutics position peaked at $3.69M in Q3 2025.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.